Homology Medicines, Inc. announced that Albert Seymour, Ph.D., Chief Scientific Officer, has been promoted to President of Homology. In addition to his role as CSO, Dr. Seymour will assume broader responsibilities for additional functional areas, including human resources, clinical development and operations, and commercial strategy.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
20.65 USD | -0.77% | -19.02% | +88.69% |
05-21 | Leerink Partners Starts Q32 Bio With Outperform Rating | MT |
05-09 | Q32 Bio Inc. Provides Corporate Update | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+88.69% | 247M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+0.73% | 22.78B | |
-10.70% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- QTTB Stock
- News Q32 Bio Inc.
- Homology Medicines, Inc. Announces Promotion of Albert Seymour to President